The Cancer Letter

Susan Ellenberg started out as a high school math teacher—then became a leading biostatistician.
https://cancerhistoryproject.com/article/susan-ellenberg-high-school-teacher-to-leading-biostatistician/

Evaluation of cancer care in Ukraine shows good access to treatment despite wartime. Guest editorial by The Global Medical Knowledge Alliance.

Photo credit: Oleksiy Samsonov; Kyiv, March 2022
https://cancerletter.com/guest-editorial/20241025_3/

NCI’s myeloMATCH will use biomarkers to match patients with myeloid cancer to trials.
https://cancerletter.com/clinical/20241025_2/

GRAIL’s woes raise questions about the prospects of MCDs and standards for their evaluation.
https://cancerletter.com/clinical/20241025_1/

Randomized trial failed to accrue, but data point to preoperative chemo as viable option in sinonasal cancer.
https://cancerletter.com/clinical/20241018_4/

Is nivolumab superior to standard of care for classic Hodgkin lymphoma? Phase III trial finds improved PFS, side effects with nivolumab+chemo.
https://cancerletter.com/clinical/20241018_3/

American Cancer Society board member Wayne Frederick steps in as interim CEO, replacing Karen Knudsen. National search will be conducted.
https://cancerletter.com/the-cancer-letter/20241018_2/

How the 2024 elections can impact cancer policy. Guest editorial by Samyukta Mullangi and Debra Patt.
https://cancerletter.com/guest-editorial/20241018_5/

Climate change exacerbates cancer disparities: Amid disasters, oncologists see urgent need for methodologies, metrics for gauging the problem.
https://cancerletter.com/the-cancer-letter/20241018_1/

Cancer clinical trials shouldn’t discriminate—but they do. Guest editorial by Erin Miller (Lazarex Cancer Foundation).
https://cancerletter.com/trials-and-tribulations/20241011_3/

In the aftermath of Helene and Milton, oncologists resort to airlifts to keep treatments on schedule.
https://cancerletter.com/the-cancer-letter/20241011_2/

Latino oncology leaders discuss representation in clinical trials, translational research, and health care.
https://cancerhistoryproject.com/article/latino-oncology-leaders-discuss-representation-in-clinical-trials-translational-research-and-health-care/

Tom Lynch (Fred Hutch) reflects on discovery of the EGFR mutations’ role in lung cancer.
https://cancerhistoryproject.com/people/tom-lynch-reflects-on-discovery-of-the-egfr-mutations-role-in-lung-cancer/

NCI-designated Basic Laboratory Cancer Centers get research done—efficiently. Guest editorial by Ze’ev Ronai.
https://cancerletter.com/guest-editorial/20241004_3/

Undergrad intern at Memorial Sloan Kettering Cancer Center poses a profound question: What if Henrietta Lacks had a Black doctor?
https://cancerletter.com/conversation-with-the-cancer-letter/20241004_2/

ODAC votes decisively in support of PD-L1 expression as predictive biomarker for checkpoint inhibitors.
https://cancerletter.com/regulatory-news/20241004_1/

How First Lady Betty Ford and surgeon Bernie Fisher revolutionized America’s attitude toward breast cancer
Guest editorial by Stacy Wentworth.
https://cancerhistoryproject.com/article/how-first-lady-betty-ford-and-surgeon-bernie-fisher-revolutionized-americas-attitude-toward-breast-cancer/

PubMed’s failure to display all papers by authors who publish under multiple names “mistreats women,” lawsuit contends.
https://cancerletter.com/the-cancer-letter/20240927_3/

ODAC votes overwhelmingly in support of PD-L1 expression as predictive biomarker for efficacy of checkpoint inhibitors.
https://cancerletter.com/regulatory-news/20240927_2/

New FDA mandate to tell patients whether their breasts are “dense” or “not dense” baffles doctors.
https://cancerletter.com/regulatory-news/20240927_1/

American Association for Cancer Research (AACR) progress report highlights AI’s role in research and clinical care.
Obstacles to progress include systemic disparities and dwindling appropriations
https://cancerletter.com/the-cancer-letter/20240920_4/

Group chairs propose funding strategy to jump-start correlative studies. Guest editorial by Peter J. O'Dwyer (ECOG-ACRIN Cancer Research Group).
https://cancerletter.com/guest-editorial/20240920_3/

2024 Lasker Awards honor discoveries in antitumor immunity, GLP-1-based drugs, and research, advocacy in HIV/AIDS.
https://cancerletter.com/the-cancer-letter/20240920_6/

Melanoma investigators invite FDA to publicly discuss approval endpoints and crossover design. The agency accepts the invitation
https://cancerletter.com/regulatory-news/20240920_2/

Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine.

Mace Rothenberg’s museum will tell the stories behind breakthroughs in medicine - The Cancer Letter Mace Rothenberg has stayed busy since stepping down as Pfizer’s chief medical officer in 2021 by pivoting to an ambitious endeavor in science communication: the Museum of Medicine and Biomedical Discovery.  To access this subscriber-only content please log in or subscribe.If your institution has ...